Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results…
Ana Vivancos
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…
VHIO takes part in this European project to expand tumour genome interpretation for personalised cancer treatment 21 – 23 November…
Co-authored by Ana Vivancos, Principal Investigator of VHIO’s Cancer Genomics Group, and VHIO’s Director Josep Tabernero, a News & Views…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
Barcelona, June 18, 2021. VHIO’s MYC ‘Masters’, Laura Soucek and Jonathan Whitfield, have shared their expertise alongside other leading figures in…
Launched by the American Association for Cancer Research (AACR) back in 2015, the AACR Project Genomics Evidence Neoplasia Information Exchange…
During 2021, the Vall d’Hebron Institute of Oncology will be the first center in Europe to establish a liquid biopsy…
